China 1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs

Indian pharmaceutical and biotech sectors have started witnessing tangible benefits from the global shift away from China, as early signs of the China 1 strategy materialising emerge, according to a recent Goldman Sachs report.

Companies